Enlivex Therapeutics (ENLV) Competitors $1.39 -0.09 (-6.08%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.36 -0.02 (-1.80%) As of 08/5/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. ZNTL, ANIX, OKYO, ONCY, IPA, CLYM, PLRX, ABOS, IVVD, and ADAGShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Zentalis Pharmaceuticals (ZNTL), Anixa Biosciences (ANIX), OKYO Pharma (OKYO), Oncolytics Biotech (ONCY), ImmunoPrecise Antibodies (IPA), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Acumen Pharmaceuticals (ABOS), Invivyd (IVVD), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Zentalis Pharmaceuticals Anixa Biosciences OKYO Pharma Oncolytics Biotech ImmunoPrecise Antibodies Climb Bio Pliant Therapeutics Acumen Pharmaceuticals Invivyd Adagene Enlivex Therapeutics (NASDAQ:ENLV) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Is ENLV or ZNTL more profitable? Enlivex Therapeutics' return on equity of -57.67% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Zentalis Pharmaceuticals N/A -65.48%-51.05% Which has more risk and volatility, ENLV or ZNTL? Enlivex Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Which has stronger earnings and valuation, ENLV or ZNTL? Enlivex Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-2.11Zentalis Pharmaceuticals$67.43M1.50-$165.84M-$3.13-0.45 Do analysts rate ENLV or ZNTL? Enlivex Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 619.42%. Zentalis Pharmaceuticals has a consensus target price of $8.37, indicating a potential upside of 493.38%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than Zentalis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to ENLV or ZNTL? In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 2 mentions for Enlivex Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 1.05 beat Enlivex Therapeutics' score of -0.33 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in ENLV or ZNTL? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryEnlivex Therapeutics beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35M$2.53B$5.59B$9.53BDividend YieldN/A1.77%4.73%4.14%P/E Ratio-2.119.1628.9223.88Price / SalesN/A717.24445.6298.82Price / CashN/A159.4135.6858.35Price / Book1.395.078.165.60Net Income-$15.01M$31.61M$3.25B$265.26M7 Day Performance-9.74%-0.38%1.18%-0.14%1 Month Performance18.30%5.79%8.27%6.08%1 Year Performance9.45%3.58%29.20%24.22% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics2.4882 of 5 stars$1.39-6.1%$10.00+619.4%+13.0%$35MN/A-2.1170Short Interest ↑ZNTLZentalis Pharmaceuticals2.2777 of 5 stars$1.44-2.0%$8.37+481.0%-58.9%$105.77M$67.43M-0.46160News CoveragePositive NewsUpcoming EarningsANIXAnixa Biosciences3.6902 of 5 stars$3.29+2.2%$9.00+173.6%+1.6%$103.72MN/A-8.665Analyst ForecastOKYOOKYO Pharma3.2085 of 5 stars$2.73-0.7%$7.00+156.4%+233.7%$103.43MN/A0.007Positive NewsUpcoming EarningsONCYOncolytics Biotech2.4545 of 5 stars$1.09+3.8%$4.33+297.6%-3.4%$99MN/A-3.7630Upcoming EarningsIPAImmunoPrecise Antibodies2.108 of 5 stars$2.02-6.5%$4.00+98.0%+122.9%$98.85M$24.00M-1.7480Short Interest ↑Analyst RevisionGap UpCLYMClimb Bio2.7193 of 5 stars$1.60+10.3%$9.00+462.5%N/A$97.99MN/A-0.679News CoveragePositive NewsUpcoming EarningsHigh Trading VolumePLRXPliant Therapeutics3.6534 of 5 stars$1.59+1.3%$13.31+737.3%-86.6%$96.38M$1.58M-0.4490News CoverageABOSAcumen Pharmaceuticals2.5818 of 5 stars$1.46-7.0%$6.33+333.8%-51.9%$95.10MN/A-0.7520News CoveragePositive NewsUpcoming EarningsIVVDInvivyd3.032 of 5 stars$0.84+6.7%$5.85+598.7%-31.0%$94.17M$25.38M-0.70100Upcoming EarningsGap UpADAGAdagene2.5292 of 5 stars$1.99-0.2%$8.00+302.8%-26.8%$93.75M$100K0.00260Gap Up Related Companies and Tools Related Companies ZNTL Competitors ANIX Competitors OKYO Competitors ONCY Competitors IPA Competitors CLYM Competitors PLRX Competitors ABOS Competitors IVVD Competitors ADAG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts